(AOF) – Medesis Pharma gains 5.54% to 1.43 euro after having received the agreement (“Notice of Allowance”) for the registration in the United States of its patent protecting for 20 years the property of its drug candidate NanoManganese radiation protection. This biotechnology company is developing a radiomitigation treatment administered during or within minutes/hours following overexposure to ionizing radiation. It is intended for the treatment of civilian and military personnel (dual technology) subjected to irradiation.
This irradiation can be of industrial, medical, accidental or military origin, external or internal.
Studies have been carried out on irradiated animals, with very favorable results allowing survival of all animals during irradiation at an LD50 dose (after which 50% of animals die within 10 days). A very important element in radiation protection, the activity is observed in radiation mitigation, that is to say effective when the administration takes place within 24 hours following irradiation.
AOF – LEARN MORE
Find out more about the “pharmacy” sector
Loss of speed in European research
European research is losing ground to American and Chinese research. In twenty years, Europe’s share has fallen from 41% to 31% in global R&D. China’s share jumped from 1% to 8%. As for the United States, which supplanted Europe, in 2001 it devoted only 2 billion euros per year more than Europe to R&D, whereas now this gap has reached 25 billion! Some experts accuse the European authorities of not having deployed effective policies. The financing of pharmaceutical research should therefore have been better targeted via the “Horizon 2020” programme. France only comes in eighteenth position in European funding despite the quality of its research. Conversely, the United States concentrates funding on Boston and a few centers of excellence.
2023-07-04 09:11:00
#Medesis #Pharma #rise #registration #patent #United #States
